Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction using natriuretic peptides: Results from the Dallas Heart Study
Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction using natriuretic peptides: Results from the Dallas Heart Study
复制标题
DOI：
10.1016/j.ahj.2008.12.017
复制
发表时间：
2009-04-01
影响因子：
4.8
通讯作者：
Drazner, Mark H.
中科院分区：
文献类型：
--
作者：
de Lemos, James A.;McGuire, Darren K.;Drazner, Mark H.
在社区中识别出左心室收缩功能障碍（LVSD）或左心室肥大（LVH）的个体可能允许更早地开始改善疾病的治疗。我们对B型利钠肽（BNP）和N末端BNP前体的筛查性能进行了综合评价方法在达拉斯心脏研究中登记的2，429名没有心力衰竭、心肌梗死、瓣膜异常或血清肌酐>2.0 mg/dL病史的受试者中，结果B型利钠肽和NT-proBNP与MRI定义的LVH和LVSD（射血分数）显著相关
Background Identification of individuals in the community with left ventricular systolic dysfunction (LVSD) or left ventricular hypertrophy (LVH) may allow earlier initiation of disease-modifying treatment. We performed a comprehensive evaluation of the screening performance of B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) for LVSD or LVH.Methods In 2,429 subjects without a history of heart failure, myocardial infarction, valvular abnormalities, or a serum creatinine >2.0 mg/dL enrolled in the Dallas Heart Study, measurement of BNP and NT-proBNP and cardiovascular magnetic resonance imaging were performed.Results B-type natriuretic peptide and NT-proBNP were robustly associated with magnetic resonance imaging-defined LVH and LVSD (ejection fraction